drugset / Trial / NCT07528703
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Participants
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase 1A, first in human, randomized, double-blinded, placebo-controlled, dose escalation study of RC010 in healthy adult volunteers. RC010 is a small-molecule drug , being developed as a novel therapeutic treatment for patients with Idiopathic Pulmonary fibrosis (IPF). This study aims to evaluate the safety, tolerability and pharmacokinetics of RC010 after Single ascending doses .
Timeline
- Start
- 2026-04
- Primary completion
- 2027-04
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RC010 | Small molecule | 0.1 mg | Inhaled |
| Subject | RC010 | Small molecule | 0.3 mg | Inhaled |
| Subject | RC010 | Small molecule | 0.75 mg | Inhaled |
| Subject | RC010 | Small molecule | 1.5 mg | Inhaled |
| Subject | RC010 | Small molecule | 2 mg | Inhaled |